Clinical trial
Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV…
NCT00004184 · University of Alabama at Birmingham, Other · Completed
Key facts
| NCT number | NCT00004184 |
|---|---|
| Title | Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma |
| Official title | A Phase I/II Trial of a Human Anti-Idiotypic Monoclonal Antibody Vaccine (4B5) Which Mimics the GD2 Antigen, in Patients With Melanoma |
| Lead sponsor | University of Alabama at Birmingham, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological, Drug |
| Interventions | monoclonal antibody 4B5 anti-idiotype vaccine, sargramostim, alum adjuvant |
| Enrollment | 50 |
| Start date | Aug 1, 1998 |
| Primary completion | Jun 1, 2001 |
| Completion | Jun 1, 2001 |
| First posted | Sep 16, 2004 |
| Last update posted | Apr 12, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: